These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
663 related articles for article (PubMed ID: 33739857)
1. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857 [TBL] [Abstract][Full Text] [Related]
2. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963 [TBL] [Abstract][Full Text] [Related]
3. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Budde LE; Assouline S; Sehn LH; Schuster SJ; Yoon SS; Yoon DH; Matasar MJ; Bosch F; Kim WS; Nastoupil LJ; Flinn IW; Shadman M; Diefenbach C; O'Hear C; Huang H; Kwan A; Li CC; Piccione EC; Wei MC; Yin S; Bartlett NL J Clin Oncol; 2022 Feb; 40(5):481-491. PubMed ID: 34914545 [TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
5. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. Bender B; Li CC; Marchand M; Turner DC; Li F; Vadhavkar S; Wang B; Deng R; Lu J; Jin J; Li C; Yin S; Wei M; Chanu P Clin Transl Sci; 2024 Jun; 17(6):e13825. PubMed ID: 38808543 [TBL] [Abstract][Full Text] [Related]
7. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Dickinson MJ; Carlo-Stella C; Morschhauser F; Bachy E; Corradini P; Iacoboni G; Khan C; Wróbel T; Offner F; Trněný M; Wu SJ; Cartron G; Hertzberg M; Sureda A; Perez-Callejo D; Lundberg L; Relf J; Dixon M; Clark E; Humphrey K; Hutchings M N Engl J Med; 2022 Dec; 387(24):2220-2231. PubMed ID: 36507690 [TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Bröske AE; Korfi K; Belousov A; Wilson S; Ooi CH; Bolen CR; Canamero M; Alcaide EG; James I; Piccione EC; Carlile DJ; Dimier N; Umaña P; Bacac M; Weisser M; Dickinson M Blood Adv; 2022 Feb; 6(3):1025-1037. PubMed ID: 34941996 [TBL] [Abstract][Full Text] [Related]
9. Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan. Hsu YT; Wu SJ; Kao HW; Hsiao SY; Liao CK; Chen TY; Wang MC Cancer; 2024 Jun; 130(11):1972-1981. PubMed ID: 38306242 [TBL] [Abstract][Full Text] [Related]
10. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas. Polgarova K; Trneny M Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755 [TBL] [Abstract][Full Text] [Related]